Our Portfolio
Mylexa is a biotech start-up, developing novel drugs for the treatment of allergic diseases such as hayfever and asthma. The company owns protected intellectual property developed in the ANU. Strong alliances are being formed to promote rapid progression of this exciting technology. See www.mylexa.com
Warm Contact designs and manufactures products which increase the comfort of patients using eye care treatments. The Company's first product is a lens warmer that offers increased patient comfort and is particularly useful to new users of contact lens who experience the anxiety surrounding the initial shock of inserting cool lenses into their eyes. See www.warmcontact.com
Dosimetry & Imaging (D&I) is a Company focused on the development of a novel X-ray storage phosphor for use in radiation detection (dosimetry) and medical imaging. New markets around the technology are emerging, and D&I is well placed to capture the growth. Exposure to radiation is a serious health concern, and D&I can potentially measure life-time exposure and reduce an individual's exposure. The patented technology comes from ADFA, UNSW and is clearly superior to its competitors. See www.dosimetryimaging.com
Synergetic Services Pty Ltd is a software development company aiming to revolutionise the process by which applicants source personal loans when shopping online for major purchases such as motor vehicles. The company has created a personal loan procurement system which empowers consumers; enables choice of loan product and financial institution; performs real-time identity and credit validation and approval of loan applications. When linked with online-market sales, a person can choose a new or used motor vehicle and apply for finance at the same time and receive immediate loan confirmation. Alternatively, a pre-approved spending level can also be obtained in the same manner. Synergetic Services is currently undergoing further capital investment. See www.synserv.com.au
The focus of Savine Therapeutics is to develop and commercialise vaccines for prevention and treatment of diseases with a significant unmet medical need using it's proprietary Scrambled Antigen Vaccine (SAVINE) technology. The technology was invented by researchers in the John Curtin School of Medical Research at the Australian National University. It enables production of vaccines suitable for a broad range of serious worldwide infectious diseases and cancers. See www.savine.com.au